Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Inclusion Criteria:

• The participant (or legally acceptable representative if applicable) provideswritten informed consent for the trial.

• Subjects with histologically or cytologically confirmed advanced or metastaticesophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed ontreatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administeredeither as monotherapy, or in combination with other therapies

• Have measurable disease per RECIST v 1.1. as assessed by local siteinvestigator/radiology

• Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Life expectancy of at least 3 months

Exclusion Criteria:

• A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatmentor breast-feeding women

• Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drugand throughout the trial

• Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timelineduration of five half-lives prior to starting study drug and throughout the trial

• Has received prior radiotherapy within 2 weeks of start of study treatment or havehad a history of radiation pneumonitis

• Has had an allogeneic tissue/solid organ transplant